fosinopril (monopril) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.   NCATS

Chemistry

  • SMILES: CCC(=O)O[C@@H](O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C
  • InChIKey: BIDNLKIUORFRQP-XYGFDPSESA-N
  • Mol. Mass: 563.67
  • ALogP: 6.12
  • ChEMBL Molecules:
    fosinopril  
    fosinopril sodium  
    fosinoprilat  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: Yes

Drug Pricing (per unit)

Australia

$0.1186 - $0.1734

United States

$0.1407 - $0.3573
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( fosinopril (monopril), hydrochlorothiazide (esidrix) )

Alternative names

(2s,4s)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid | (2s,4s)-4-cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid | fosenopril | fosenopril sodium | fosinapril | fosinopril | fosinoprilat | fosinopril sodium | fositens | fozitec | monopril | (s)-4-cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid | sq-28555 | staril

Organizations (39)

Research & Development (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (18)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (2)


 

Heart Failure

Hypertension

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Albuminuria (Phase 3)

Cardiovascular Diseases (Phase 3)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Nephropathies (Phase 2)

Heart Diseases (Phase 4)

Hypertension (Phase 2)

Hypotension (Phase 4)

Kidney Diseases (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial Organizations: 22

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue